FASEB Science Research Conference: Melatonin Biology: Actions and Therapeutics

January 26, 2015

Bethesda, MD - The 2015 FASEB Science Research Conference Melatonin Biology: Actions and Therapeutics will focus on the role of melatonin and its analogues as potential drugs in the treatment of sleep and circadian disorders, insomnia, cancer, immune dysfunction, inflammatory processes, and neurodegenerative disease. The information presented will range from the continuing identification of a new role for melatonin in supporting health to the understanding of melatonin receptors in the diagnosis and prevention of human disease. This fourth international conference is the only one of its kind to bring together investigators from around the world with an interest in studying melatonin and its biology for the purpose of developing novel therapeutic agents.

FASEB has announced a total of 34 Science Research Conferences (SRC) in 2015. Registration opens January 20, 2015. For more information about an SRC, view preliminary programs, or find a listing of all our 2015 SRCs, please visit http://www.faseb.org/SRC.
-end-
Since 1982, FASEB SRC has offered a continuing series of inter-disciplinary exchanges that are recognized as a valuable complement to the highly successful society meetings. Divided into small groups, scientists from around the world meet intimately and without distractions to explore new approaches to those research areas undergoing rapid scientific changes.

In efforts to expand the SRC series, potential organizers are encouraged to contact SRC staff at SRC@faseb.org. Proposal guidelines can be found at http://www.faseb.org/SRC.

FASEB is composed of 27 societies with more than 120,000 members, making it the largest coalition of biomedical research associations in the United States. Our mission is to advance health and welfare by promoting progress and education in biological and biomedical sciences through service to our member societies and collaborative advocacy.

Federation of American Societies for Experimental Biology
9650 Rockville Pike, Bethesda, MD 20814-3998
http://www.faseb.org/SRC-Mela

Contact: Kristen Hagy, CMP
Office of Scientific Meetings & Conferences
301-634-7010
src@faseb.org

MELATONIN BIOLOGY: ACTIONS AND THERAPEUTICS
Date: July 19-24, 2015, Lisbon, Portugal
Organizer Name: James Olcese, Nava Zisapel

Federation of American Societies for Experimental Biology

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.